UNSPSC 51383200: Nonsteroidal anti inflammatory indans

Nonsteroidal anti inflammatory drugs made from Aryl cyclopentanes that are a reduced (protonated) form of indenes.

UNSPSC 51383200 Nonsteroidal anti inflammatory indans is a Class code, but the recent state and local opportunities posted under this code do not align with its nominal scope. The three opportunities on record—a Florida county's procurement of naloxone and drug deactivation systems, a Texas HHS Request for Information on direct-to-manufacturer prescription programs, and a Minnesota cooperative purchasing RFP for generic multi-source pharmaceuticals and OTC products—involve pharmaceutical procurement and benefit management rather than nonsteroidal anti-inflammatory drugs specifically. The mismatch suggests either persistent miscoding in the source systems or that jurisdictions are using the UNSPSC category as a catch-all for broader pharmaceutical purchasing. State and local buyers posting under this code are a mixed set: county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). The issuing bodies span regional health authorities and state procurement offices rather than a concentrated buyer base.

Recent activity clusters in the Southeast and upper Midwest, with named opportunities from Florida, Texas, and Minnesota. Seminole County issued IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: the posted date and response date are inconsistent in the source). The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs before issuing a formal RFP. MMCAP released an RFP (S1070000015802) on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, including Oregon, with contract effectiveness July 1, 2026. The MMCAP solicitation is the most prescriptive, requiring cGMP and Drug Supply Chain Security Act compliance, specific insurance coverage limits, and pricing submissions through designated wholesalers. The Texas RFI represents exploratory procurement ahead of formal solicitation. Given the code-scope mismatch and the lack of clarity in posted opportunity descriptions, this code shows limited signal for targeted pursuit without further investigation of how individual jurisdictions actually tag pharmaceutical procurements.